Anti-Gout Preparation (NSAIDs and Antigout Preparations)
Manufacturer:Square Pharmaceuticals Ltd.
Indication: BarifTM is indicated for the chronic management of hyperuricemia in patients with gout. BarifTM is not recommended for the treatment of asymptomatic hyperuricemia.
Dosage & Administration: BarifTM is recommended at 40 mg or 80 mg once daily. The recommended starting dose of Barif is 40 mg once daily. For patients who do not achieve a serum uric acid less than 6 mg /dL after 2 weeks with 40 mg, BarifTM 80 mg is recommended. BarifTM can be administered without regard to food or antacid use. No dose adjustment is necessary when administering Febuxostat to patients with mild to moderate renal or hepatic impairment.